HSK36273 + Heparin sodium
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Renal Replacement Therapy
Conditions
Renal Replacement Therapy
Trial Timeline
Nov 1, 2022 → Oct 1, 2023
NCT ID
NCT05602129About HSK36273 + Heparin sodium
HSK36273 + Heparin sodium is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Renal Replacement Therapy. The current trial status is unknown. This product is registered under clinical trial identifier NCT05602129. Target conditions include Renal Replacement Therapy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05602129 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Renal Replacement Therapy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109 | MBX Biosciences | Phase 1 | 28 |
| LY3473329 | Eli Lilly | Phase 1 | 33 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| Drotrecogin alfa activated (Xigris) | Eli Lilly | Phase 2 | 52 |
| LY3819469 | Eli Lilly | Phase 1 | 33 |
| Atezolizumab + Cabozantinib | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-6000a + DS-6000a | Daiichi Sankyo | Phase 1 | 33 |
| DS-1093a | Daiichi Sankyo | Phase 1 | 33 |
| CS-3150 | Daiichi Sankyo | Phase 3 | 77 |
| AGS-16C3F | Astellas Pharma | Phase 1 | 33 |
| AGS-16M8F | Astellas Pharma | Phase 1 | 33 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| YM178 | Astellas Pharma | Phase 1 | 33 |
| intravenous immunoglobulins (IVIG) | Astellas Pharma | Phase 1 | 33 |
| bixalomer | Astellas Pharma | Pre-clinical | 23 |